Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty

This study has been terminated.
(Sponsor decision)
Sponsor:
Information provided by (Responsible Party):
Amp Orthopedics, Inc.
ClinicalTrials.gov Identifier:
NCT01475604
First received: November 17, 2011
Last updated: July 6, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to determine the effectiveness of pulsed radio frequency (PRF), a type of electromagnetic field treatment with the Ivivi Torino II for reducing post-operative narcotic use in patients recovering from Total Knee Arthroplasty.


Condition Intervention Phase
Osteoarthritis, Knee
Device: Ivivi Torino II
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty: A Double-Blind, Randomized, Sham-controlled Trial

Resource links provided by NLM:


Further study details as provided by Amp Orthopedics, Inc.:

Primary Outcome Measures:
  • The average daily morphine equivalent dose consumption at 2 weeks post-surgery. [ Time Frame: 2-week follow-up period from surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Post-surgical opioid use during hospitalization and following discharge at 1 and 4 weeks post-surgery. [ Time Frame: 1 and 4 weeks post-surgery ] [ Designated as safety issue: No ]
  • Knee pain severity assessed on a 10 cm visual analogue scale (VAS) [ Time Frame: At intervals over the 4-week follow-up period ] [ Designated as safety issue: No ]
    Knee pain will be assessed for "current", pain at the time of data collection and "maximum", maximum pain experience at any point during the day of evaluation

  • The measurement of knee joint circumference [ Time Frame: Measurement performed preoperatively, on the first or second postoperative day, at the discharge dressing change, and at the 4 week follow-up visit ] [ Designated as safety issue: No ]
    With patient in supine position, the circumference of the extended knee will be measured 1 cm proximal to the base of the patella using the same type of tape measure in all patients

  • Range of motion of the knee joint, assessed using the knee flexion technique [ Time Frame: Assessed preoperatively, on the first or second postoperative day, at the discharge dressing change (unless discharged within 2 days), and at the 4 week follow-up visit ] [ Designated as safety issue: No ]
    Range of motion will be assessed using the knee flexion technique, which allows the use of a goniometer with the trans-epicondylar axis of the knee joint as the fulcrum.

  • OA-related medication use including analgesics, anti-inflammatories, and other non-opioids [ Time Frame: 4 weeks post-surgery ] [ Designated as safety issue: No ]
    Subjects will be required to track daily OA-related medication use including analgesics, anti-inflammatories, and other non-opioids using a daily diary.

  • Adverse Events collected and analyzed for confirmation of device safety [ Time Frame: Randomization to 4 weeks post-surgery ] [ Designated as safety issue: No ]
    Subjects will be instructed by the research staff and in the instructions in the daily diary to contact the research staff and/or investigator with any adverse events (AEs). Adverse events will be recorded daily.


Enrollment: 23
Study Start Date: November 2011
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Targeted pulsed electromagnetic field Device: Ivivi Torino II
Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
Other Name: Electromagnetic Field Therapy
Sham Comparator: Sham Device: Ivivi Torino II
Sham treatment for 4 weeks post-surgery
Other Name: Electromagnetic Field Therapy

Detailed Description:

Surgeons are continually looking for means to minimize postoperative pain following TKA in order to reduce or eliminate the need for opioid pain medications. Reductions in pain and edema along with improvements in range of motion encourage quicker recovery of joint function and normal activities. Pulsed radio frequency (PRF), a type of electromagnetic field treatment is proven to effectively modulate postoperative pain and edema in plastic surgery. Therefore, PRF has potential as an adjunct therapy for patients recovering from TKA.

The purpose of the current double-blind, randomized, sham-controlled clinical trial is to determine the effectiveness and safety of the Ivivi Torino II, a device that delivers pulsed radio frequency (PRF), a type of electromagnetic field treatment, in patients recovering from TKA for treatment of severe knee OA.

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 40 to 80 years
  • Primary diagnosis of knee OA
  • Appropriate candidate for TKA
  • Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects
  • Consent to the study and willing to comply with study product and methods including follow-up

Exclusion Criteria:

  • Body mass index > 40 kg/m2
  • Scheduled for bilateral TKA
  • Advanced hip, spine, or ankle osteoarthritis that significantly limits ambulation
  • Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverter-defibrillator)
  • Use of narcotic pain medication for any condition in the last 1 month prior to surgery
  • Self-reported diagnosis of post-traumatic or inflammatory arthritis (e.g. rheumatoid or psoriatic)
  • Pregnant or lactating female
  • Participation in any clinical trial in the past 30 days
  • Vulnerable populations including prisoners and nursing home residents
  • Any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01475604

Locations
United States, Virginia
Anderson Orthopaedic Research Institute
Alexandria, Virginia, United States, 22306
Sponsors and Collaborators
Amp Orthopedics, Inc.
Investigators
Principal Investigator: Gerard A. Engh, M.D. Anderson Orthopaedic Research Institute
  More Information

No publications provided

Responsible Party: Amp Orthopedics, Inc.
ClinicalTrials.gov Identifier: NCT01475604     History of Changes
Other Study ID Numbers: IOH-TKA-001
Study First Received: November 17, 2011
Last Updated: July 6, 2012
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Amp Orthopedics, Inc.:
Pulsed Radio Frequency, Electromagnetic Field therapy

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on November 20, 2014